BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 31086024)

  • 1. GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.
    Fu Y; Liu CJ; Kobayashi DK; Johanns TM; Bowman-Kirigin JA; Schaettler MO; Mao DD; Bender D; Kelley DG; Uppaluri R; Bi WL; Dunn IF; Tao Y; Luo J; Kim AH; Dunn GP
    Sci Rep; 2020 Jun; 10(1):9027. PubMed ID: 32493985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the programmed death-1 pathway in lymphoid neoplasms.
    Ok CY; Young KH
    Cancer Treat Rev; 2017 Mar; 54():99-109. PubMed ID: 28242522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment.
    Umezu D; Okada N; Sakoda Y; Adachi K; Ojima T; Yamaue H; Eto M; Tamada K
    Cancer Immunol Immunother; 2019 Feb; 68(2):201-211. PubMed ID: 30357491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering Cholesterol's Role in PD-L2 Stability: A Distinct Regulatory Mechanism From PD-L1.
    Zhang Y; Xiao T; Wen M; Shen L; Du L; Wei S; Wu B; Yu Y; Wang S; OuYang B
    J Mol Biol; 2024 Apr; 436(8):168500. PubMed ID: 38401626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response.
    Dioken DN; Ozgul I; Yilmazbilek I; Yakicier MC; Karaca E; Erson-Bensan AE
    Cancer Immunol Immunother; 2023 Dec; 72(12):4065-4075. PubMed ID: 37768345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helminth-induced Ly6C
    Terrazas C; de Dios Ruiz-Rosado J; Amici SA; Jablonski KA; Martinez-Saucedo D; Webb LM; Cortado H; Robledo-Avila F; Oghumu S; Satoskar AR; Rodriguez-Sosa M; Terrazas LI; Guerau-de-Arellano M; Partida-Sánchez S
    Sci Rep; 2017 Jan; 7():40814. PubMed ID: 28094319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.
    Xu S; Wang C; Yang L; Wu J; Li M; Xiao P; Xu Z; Xu Y; Wang K
    Front Immunol; 2023; 14():1199631. PubMed ID: 37313405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis.
    Veitch S; Radia DH
    Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis.
    Wan B; Deng P; Dai W; Wang P; Dong Z; Yang C; Tian J; Hu T; Yan K
    Medicine (Baltimore); 2021 Apr; 100(14):e25315. PubMed ID: 33832105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mast Cells: Fascinating but Still Elusive after 140 Years from Their Discovery.
    Varricchi G; Marone G
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
    Xu Y; Wu Y; Zhang S; Ma P; Jin X; Wang Z; Yao M; Zhang E; Tao B; Qin Y; Chen H; Liu A; Chen M; Xiao M; Lu C; Mao R; Fan Y
    Cell Rep; 2019 Dec; 29(11):3435-3447.e4. PubMed ID: 31825827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
    Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
    Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the important roles of tumor cell-intrinsic PD-1.
    Zheng H; Ning Y; Zhan Y; Liu S; Wen Q; Fan S
    Int J Biol Sci; 2021; 17(10):2537-2547. PubMed ID: 34326692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Expression in Mastocytosis.
    Williams M; Lidke DS; Hartmann K; George TI
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31086024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
    Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
    Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
    Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
    Front Immunol; 2020; 11():596825. PubMed ID: 33424844
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.